CN101616892A - 用于治疗铁失调的三环化合物 - Google Patents

用于治疗铁失调的三环化合物 Download PDF

Info

Publication number
CN101616892A
CN101616892A CN200880005559A CN200880005559A CN101616892A CN 101616892 A CN101616892 A CN 101616892A CN 200880005559 A CN200880005559 A CN 200880005559A CN 200880005559 A CN200880005559 A CN 200880005559A CN 101616892 A CN101616892 A CN 101616892A
Authority
CN
China
Prior art keywords
replaces
optional
independently
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880005559A
Other languages
English (en)
Chinese (zh)
Inventor
麦克海里·乔威夫
纳加斯瑞·柴卡
琼-杰克库·卡迪厄
傅健民
拉金德·坎博日
维什努墨西·库德穆鲁
乔纳森·朗吉乐
刘世峰
孙建宇
塞尔戈·斯维里多夫
张载辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CN101616892A publication Critical patent/CN101616892A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/08—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing three- or four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880005559A 2007-03-07 2008-03-07 用于治疗铁失调的三环化合物 Pending CN101616892A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89358507P 2007-03-07 2007-03-07
US60/893,585 2007-03-07

Publications (1)

Publication Number Publication Date
CN101616892A true CN101616892A (zh) 2009-12-30

Family

ID=39512833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880005559A Pending CN101616892A (zh) 2007-03-07 2008-03-07 用于治疗铁失调的三环化合物

Country Status (13)

Country Link
US (1) US20090069408A1 (enExample)
EP (1) EP2061755A1 (enExample)
JP (1) JP2010520884A (enExample)
CN (1) CN101616892A (enExample)
AR (1) AR065628A1 (enExample)
AU (1) AU2008222666A1 (enExample)
BR (1) BRPI0808043A2 (enExample)
CA (1) CA2678895A1 (enExample)
CL (1) CL2008000666A1 (enExample)
MX (1) MX2009009466A (enExample)
RU (1) RU2009136996A (enExample)
TW (1) TW200845961A (enExample)
WO (1) WO2008109840A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114163417A (zh) * 2021-12-06 2022-03-11 郑州海阔光电材料有限公司 一种3-溴硫芴的合成方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2688547A1 (en) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals, Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
AR077892A1 (es) 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
TW201113274A (en) 2009-09-07 2011-04-16 Vifor Int Ag Novel ethanediamine hepcidine antagonists
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
JP6810988B2 (ja) 2015-10-23 2021-01-13 ヴィフォール （インターナショナル） アクチェンゲゼルシャフトＶｉｆｏｒ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） ＡＧ 新規なフェロポーチン阻害剤
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
JP2023177660A (ja) * 2022-06-02 2023-12-14 旭化成株式会社 ルテニウム錯体の製造方法、並びにルテニウム錯体及びこれを用いたジアミンの製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
US6310243B1 (en) * 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
US6080587A (en) * 1998-01-23 2000-06-27 Eli Lilly And Company Method for preparing and selecting pharmaceutically useful sulfur-bridged bi- and triaromatic ring compounds from a structurally diverse universal library
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US20060269498A1 (en) * 2005-05-17 2006-11-30 Gerard Malle Hair shaping composition comprising at least one polyguanidine other than hydroxide
CA2688547A1 (en) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals, Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114163417A (zh) * 2021-12-06 2022-03-11 郑州海阔光电材料有限公司 一种3-溴硫芴的合成方法

Also Published As

Publication number Publication date
AR065628A1 (es) 2009-06-17
AU2008222666A1 (en) 2008-09-12
EP2061755A1 (en) 2009-05-27
JP2010520884A (ja) 2010-06-17
RU2009136996A (ru) 2011-04-20
WO2008109840A1 (en) 2008-09-12
CL2008000666A1 (es) 2008-06-13
BRPI0808043A2 (pt) 2014-06-24
US20090069408A1 (en) 2009-03-12
MX2009009466A (es) 2009-09-15
TW200845961A (en) 2008-12-01
CA2678895A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
CN101616892A (zh) 用于治疗铁失调的三环化合物
US20080234327A1 (en) Dihydroindazole compounds useful in treating iron disorders
WO2008121861A2 (en) Pyrazole and pyrrole compounds useful in treating iron disorders
TWI833829B (zh) 聯苯類化合物，其中間體，製備方法，藥物組合物及應用
US20100240713A1 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
JP2021107425A (ja) 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2010522197A (ja) 鉄障害を治療するのに有用なビアリール化合物およびヘテロビアリール化合物
CN113518776B (zh) 苯并噻吩类化合物及其制备方法和用途
CA2381090A1 (en) Benzoic acid derivatives for the treatment of diabetes mellitus
CZ282503B6 (cs) Amidy, způsob jejich přípravy a farmaceutické komposice tyto amidy obsahující
AU2006261845A1 (en) Imidazole based LXR modulators
CA2469048A1 (en) Quinolinones as prostaglandin receptor ligands
KR20200126988A (ko) 뉴로트로핀과 관련된 질병을 치료하기 위한 트리아진 유도체
KR20190039948A (ko) Gpr40- 및 gpr120-효능제로서의 설폰아미드
AU2021411658B2 (en) 2-pyridone derivative, and preparation method therefor and pharmaceutical application thereof
JP2018039733A (ja) 新規複素環誘導体
CN115124517B (zh) 芳香族化合物、其制备方法、药物组合物和应用
JP7692481B2 (ja) ５－ｈｔ７セロトニン受容体活性阻害用ビフェニルピロリジン及びビフェニルジヒドロイミダゾール誘導体並びにこれを有効成分として含む薬学組成物
TW201404772A (zh) 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091230